Health Encyclopedia

Chloroguanide

Chloroguanide | Uses, Dosages, Side Effects and More

Introduction to Chloroguanide

Chloroguanide , also known as proguanil, is an antimalarial armacology-toxicology-and-pharmaceutical-science/therapeutic-agent” target=”_blank”>therapeutic agent used for the treatment and prevention of Plasmodium falciparum malaria. As a pro-drug, chloroguanide is metabolized in the body to its active form, cycloguanil. This article provides a comprehensive overview of chloroguanide, covering its chemical composition, mechanism of action, medical uses, side effects, and more.

Chemical Composition and Structure

Chloroguanide has the molecular formula C11H16ClN5 and a molecular weight of 253.73 g/mol. Its chemical structure includes a triazine ring and a chlorophenyl group. Chloroguanide is also known by various synonyms, including proguanil, chlorguanide, and its CAS number 500-92-5. The compound’s PubChem entry provides additional information on its chemical properties.

Prodrug Nature of Chloroguanide

Chloroguanide is a pro-drug, meaning it is converted into its active metabolite, cycloguanil, within the body. The liver enzyme CYP2C19 plays a crucial role in this metabolism process. Variations in CYP2C19 activity can influence the effectiveness of chloroguanide as an antimalarial agent.

Conversion to Active Metabolite

Once administered, chloroguanide undergoes hepatic metabolism, primarily by the CYP2C19 enzyme, to form cycloguanil. Cycloguanil is the active compound responsible for the antimalarial effects of chloroguanide. This conversion is essential for the drug’s therapeutic efficacy.

Mechanism of Action

Chloroguanide‘s antimalarial activity is attributed to its active metabolite, cycloguanil. Cycloguanil inhibits the enzyme dihydrofolate reductase (DHFR) in the malaria parasite, disrupting the parasite’s folate metabolism. By interfering with the synthesis of essential folate derivatives, cycloguanil prevents the growth and replication of the parasite in both the erythrocyte and exoerythrocyte stages of its life cycle.

Inhibition of Parasitic Dihydrofolate Reductase

Cycloguanil binds to and inhibits the malaria parasite’s DHFR enzyme, which is crucial for the synthesis of tetrahydrofolate. Tetrahydrofolate is a vital cofactor involved in the production of nucleic acids and amino acids. By inhibiting DHFR, cycloguanil disrupts the parasite’s folate cycle, leading to the depletion of folate derivatives necessary for parasite growth and survival.

Medical Uses and Indications

Chloroguanide is primarily used for the treatment and prevention of malaria caused by Plasmodium falciparum. It is often administered in combination with other antimalarial drugs, such as chloroquine, to enhance its effectiveness and reduce the risk of drug resistance.

Treatment and Prophylaxis of Malaria

Chloroguanide is indicated for the treatment of acute uncomplicated P. falciparum malaria. It is also used as a prophylactic agent to prevent malaria in travelers visiting endemic areas. The World Health Organization (WHO) recommends chloroguanide in combination with chloroquine for malaria prophylaxis in certain regions.

armacology”>Ph armacodynamics and armacokinetics/”>Ph armacokinetics

Understanding the ph armacodynamic and ph armacokinetic properties of chloroguanide is essential for optimizing its therapeutic use. Chloroguanide is readily absorbed from the gastrointestinal tract and undergoes extensive first-pass metabolism in the liver, primarily by the CYP2C19 enzyme, to form its active metabolite, cycloguanil.

Absorption, Distribution, Metabolism, and Excretion

After oral administration, chloroguanide is rapidly absorbed, with peak plasma concentrations achieved within 2-4 hours. It has a bioavailability of approximately 60%. Chloroguanide is widely distributed throughout the body, including in red blood cells, and crosses the placental barrier. The drug is extensively metabolized in the liver, with cycloguanil being the primary active metabolite. Excretion occurs mainly through the kidneys, with a half-life of 12-21 hours for chloroguanide and 10-20 hours for cycloguanil.

Administration and Dosage

Chloroguanide is administered orally in the form of tablets. The dosage regimen varies depending on the indication and patient characteristics. For malaria prophylaxis, the typical adult dose is 100-200 mg daily, starting 1-2 days before travel to an endemic area and continuing for 4 weeks after leaving the area. For the treatment of acute malaria, higher doses may be used in combination with other antimalarial agents.

Common Dosing Regimens

The following are general dosing guidelines for chloroguanide:

Combination Therapies

Chloroguanide is often used in combination with other antimalarial drugs to enhance its effectiveness and reduce the risk of drug resistance. The most common combination is with chloroquine, known as chloroquine-proguanil. This combination has been widely used for malaria prophylaxis and treatment in areas where chloroquine resistance is not prevalent.

Atovaquone plus Chloroguanide vs. Mefloquine

Another combination therapy is atovaquone plus chloroguanide, which has been shown to be effective against multidrug-resistant P. falciparum malaria. Studies have compared the efficacy and safety of atovaquone plus chloroguanide with mefloquine, another antimalarial drug. A systematic review found that atovaquone plus chloroguanide had similar efficacy to mefloquine but with a lower incidence of adverse events.

Side Effects and Adverse Reactions

Chloroguanide is generally well-tolerated, but like all medications, it can cause side effects. Common adverse reactions include gastrointestinal disturbances, such as nausea, vomiting, and diarrhea. Some patients may experience headaches, dizziness, or insomnia.

Impact on Psychiatric and Physical Well-being

In rare cases, chloroguanide has been associated with psychiatric side effects, such as depression, anxiety, and hallucinations. These adverse reactions are more likely to occur with higher doses or prolonged use. Physical side effects may include fatigue, weakness, and anemia. Patients should be monitored for any unusual symptoms and promptly report them to their healthcare provider.

Drug Interactions

Chloroguanide can interact with other medications, potentially altering their effectiveness or increasing the risk of side effects. CYP2C19 inhibitors, such as omeprazole and fluconazole, can increase cycloguanil levels, while CYP2C19 inducers, like rifampin and carbamazepine, can decrease cycloguanil concentrations.

Influence of CYP2C19 Variability

Genetic variations in the CYP2C19 enzyme can significantly impact the metabolism of chloroguanide and, consequently, its therapeutic efficacy. Individuals with reduced CYP2C19 activity (poor metabolizers) may have lower cycloguanil levels and a decreased response to chloroguanide. Conversely, those with increased CYP2C19 activity (ultrarapid metabolizers) may have higher cycloguanil concentrations and a greater risk of adverse effects. Ph armacogenetic testing can help identify patients with CYP2C19 variations and guide dosing adjustments.

Clinical Efficacy and Studies

Numerous clinical trials have evaluated the efficacy of chloroguanide in the prevention and treatment of malaria. These studies have demonstrated the drug’s effectiveness, particularly when used in combination with other antimalarial agents.

Summary of Clinical Trials

A Cochrane review analyzed the efficacy of chloroguanide for malaria prophylaxis in travelers. The review found that chloroguanide, when used in combination with chloroquine, significantly reduced the risk of malaria compared to placebo. Another meta-analysis evaluated the efficacy of atovaquone plus chloroguanide for the treatment of uncomplicated P. falciparum malaria and found high cure rates across different geographical regions.

Resistance and Prophylactic Failure

The emergence of drug resistance is a major concern in the fight against malaria. Resistance to chloroguanide has been reported in some areas, particularly in Southeast Asia and parts of Africa. Prophylactic failure can occur when resistant strains of the parasite are present.

Factors Contributing to Drug Resistance

Several factors can contribute to the development of chloroguanide resistance, including widespread use of the drug, inadequate dosing, and genetic mutations in the parasite’s DHFR enzyme. Monitoring resistance patterns and implementing strategies to mitigate resistance, such as combination therapies and rotating antimalarial regimens, are crucial for preserving the effectiveness of chloroguanide.

Commercial Availability

Chloroguanide is commercially available under various brand names, depending on the country and manufacturer. Some common brand names include Paludrine, Malarone (in combination with atovaquone), and Proguanil.

Brand Names and armaceutical/”>Ph armaceutical Companies

The following are some ph armaceutical companies that produce chloroguanide:

Research and Future Directions

Ongoing research aims to optimize the use of chloroguanide and develop new antimalarial strategies. Scientists are investigating ways to overcome drug resistance, improve drug delivery systems, and explore novel drug combinations.

Ongoing Studies and Research Areas

Some current research areas related to chloroguanide include:

Regulatory Status

Chloroguanide has been approved by various regulatory agencies worldwide for the prevention and treatment of malaria. The drug’s approval status and indications may vary depending on the country and region.

Approval Status by Health Authorities

The following are some examples of chloroguanide’s regulatory status:

Environmental and Societal Impact

Chloroguanide plays a significant role in global efforts to control and eliminate malaria. The drug’s availability and accessibility in malaria-endemic regions are crucial for reducing the burden of the disease and improving public health outcomes.

Role in Global Malaria Eradication Efforts

Malaria remains a major global health challenge, with millions of cases and hundreds of thousands of deaths reported annually. Chloroguanide, as part of combination therapies, contributes to malaria control and elimination strategies. Its use in prophylaxis helps protect travelers and vulnerable populations, while its therapeutic application aids in the treatment of acute malaria cases. Ensuring the availability and proper use of chloroguanide in endemic areas is essential for progress towards malaria eradication.

Historical Context

Chloroguanide was first synthesize

Chloroguanide